Indoramin

drug

On this page

Also known as BaratolDoralese tiltabIndoraminaIndoramineWY 21901WY-21901SID49671666SID29217568

Summary

Indoramin (CHEMBL279516) is an approved small molecule (ATC C02CA02) targeting ADRA1A, ADRA1B, and ADRA1D; indicated across 1 condition including hypertensive disorder.

At a glance

Status: Approved (max clinical phase 4)
Modality: Small molecule
ATC class: C02CA02
Targets: 3 (ADRA1A, ADRA1B, ADRA1D)
Indications: 1 condition
Chemistry: 347.5 Da · C22H25N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL279516
Name	Indoramin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	33625
ATC	C02CA02
Molecular formula	C22H25N3O
Molecular weight	347.5
InChIKey	JXZZEXZZKAWDSP-UHFFFAOYSA-N

SMILES: C1CN(CCC1NC(=O)C2=CC=CC=C2)CCC3=CNC4=CC=CC=C43

IUPAC name: N-[1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl]benzamide

Also known as: Baratol, Doralese tiltab, Indoramin, Indoramina, Indoramine, WY 21901, WY-21901, indoramin, SID49671666, SID29217568, INDORAMIN

Parent form; salt/anhydrous children: CHEMBL2104941

Patent coverage: 1,707 distinct patent families (6,216 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,157 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ADRA1A	α_1A-adrenoceptor	Antagonist	8.4		P35348
ADRA1B	α_1B-adrenoceptor	Antagonist	7.4	0%	P35368
ADRA1D	α_1D-adrenoceptor	Antagonist	6.7	0.2%	P25100

Broader ChEMBL bioactivity targets: 11 (assay-derived). Sample: Alpha-2A adrenergic receptor, Adrenergic receptor alpha-1, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Adrenergic receptor alpha-2, Adrenergic receptor alpha-1, Alpha-1D adrenergic receptor, Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor.

Bioactivity

ChEMBL activities: 14 potent at pChembl ≥ 5 of 15 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA1D	8.7	Kd	2	nM	CHEMBL_ACT_267285
ADRA1A	8.43	Ki	3.7	nM	CHEMBL_ACT_306328
ADRA1A	8.4	Ki	3.98	nM	CHEMBL_ACT_267282
P18130	7.92	Ki	12	nM	CHEMBL_ACT_306329
P15823	7.61	Ki	24.55	nM	CHEMBL_ACT_456533
ADRA1B	7.6	Ki	25	nM	CHEMBL_ACT_306327
ADRA1B	7.54	Ki	29	nM	CHEMBL_ACT_306326
ADRA1B	7.4	Ki	39.81	nM	CHEMBL_ACT_267283
ADRA1D	6.96	Ki	110	nM	CHEMBL_ACT_306324
ADRA1D	6.8	Ki	158.5	nM	CHEMBL_ACT_267284
ADRA2C	6.32	Ki	476	nM	CHEMBL_ACT_306332
ADRA2B	6.28	Ki	528	nM	CHEMBL_ACT_306331
P23944	6.21	Ki	611	nM	CHEMBL_ACT_306325
ADRA2A	5.65	Ki	2240	nM	CHEMBL_ACT_306330

Target pathways

Aggregated over 3 target gene(s): ADRA1A, ADRA1B, ADRA1D.

Top Reactome pathways

9 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	3	ADRA1A, ADRA1B, ADRA1D
Signaling by GPCR	3	ADRA1A, ADRA1B, ADRA1D
Class A/1 (Rhodopsin-like receptors)	3	ADRA1A, ADRA1B, ADRA1D
Amine ligand-binding receptors	3	ADRA1A, ADRA1B, ADRA1D
GPCR downstream signalling	3	ADRA1A, ADRA1B, ADRA1D
Adrenoceptors	3	ADRA1A, ADRA1B, ADRA1D
G alpha (q) signalling events	3	ADRA1A, ADRA1B, ADRA1D
G alpha (12/13) signalling events	3	ADRA1A, ADRA1B, ADRA1D
GPCR ligand binding	3	ADRA1A, ADRA1B, ADRA1D

Dominant GO biological processes

GO term	Targets
signal transduction	3
G protein-coupled receptor signaling pathway	3
phospholipase C-activating G protein-coupled receptor signaling pathway	3
positive regulation of cytosolic calcium ion concentration	3
cell-cell signaling	3
positive regulation of MAPK cascade	3
adenylate cyclase-activating adrenergic receptor signaling pathway	3
neuron-glial cell signaling	3
adrenergic receptor signaling pathway	3
positive regulation of cardiac muscle hypertrophy	2
intracellular signal transduction	2
positive regulation of vasoconstriction	2
regulation of muscle contraction	2
regulation of vasoconstriction	2
regulation of cardiac muscle contraction	2

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	4	MONDO:0005044	EFO:0000537

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

571 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ALFUZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
AMLODIPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
APRACLONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ASENAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ATENOLOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
AZELASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
BREXPIPRAZOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
BRIMONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
BUSPIRONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
CARIPRAZINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
CISAPRIDE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
CLONIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
CLOZAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
DEXMEDETOMIDINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
DOPAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
DOXAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
EBASTINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
EPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
FENOLDOPAM	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
HALOPERIDOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
INDACATEROL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ISOPROTERENOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
LABETALOL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
MOXISYLYTE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
NAFTOPIDIL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
NEFAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
NOREPINEPHRINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
OLANZAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
OXYMETAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
PHENTOLAMINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
PRAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
QUETIAPINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
RISPERIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
SERTINDOLE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
SILODOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TAMSULOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TEGASEROD	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TERAZOSIN	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TERFENADINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
TOLAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
VERAPAMIL	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
VILAZODONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
XYLOMETAZOLINE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
ZIPRASIDONE	ChEMBL	Phase 4 (approved)	ADRA1A, ADRA1B, ADRA1D
BUNAZOSIN	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
IDAZOXAN	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
LATREPIRDINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
MEDETOMIDINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
YOHIMBINE	ChEMBL	Phase 3	ADRA1A, ADRA1B, ADRA1D
ABANOQUIL	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
CIRAZOLINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
DEXNIGULDIPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
IPSAPIRONE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
MAZAPERTINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
NIGULDIPINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
PIPEROXAN	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
PIZOTYLINE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D
SPIRAMIDE	ChEMBL	Phase 2	ADRA1A, ADRA1B, ADRA1D

Genes: ADRA1A, ADRA1B, ADRA1D
Diseases: hypertensive disorder
Drugs: Dihydroergotamine, Alfuzosin, Amlodipine, Apraclonidine, Aripiprazole, Asenapine, Atenolol, Azelastine, Brexpiprazole, Brimonidine, Buspirone, Cariprazine, Cisapride, Clonidine, Clozapine, Dexmedetomidine, Dopamine, Doxazosin, Ebastine, Epinephrine, Fenoldopam, Haloperidol, Indacaterol, Isoproterenol, Labetalol, Moxisylyte, Naftopidil, Nefazodone, Norepinephrine, Olanzapine, Oxymetazoline, Phentolamine, Prazosin, Quetiapine, Risperidone, Sertindole, Silodosin, Tamsulosin, Tegaserod, Terazosin, Terfenadine, Tolazoline, Verapamil, Vilazodone, Xylometazoline, Ziprasidone, Bunazosin, Idazoxan, Latrepirdine, Yohimbine

Summary

Identifiers

Drug identity and classification

Targets

Targets

Bioactivity

Target pathways

Top Reactome pathways

Dominant GO biological processes

Indications & clinical

Indications

Clinical trials

Clinical evidence (CIViC)

Pharmacology

Pharmacogenomics

Related molecules

Related molecules

Related Atlas pages